Cover Image

Drug–drug interaction of microdose and regular-dose omeprazole with a CYP2C19 inhibitor and inducer

Gab-jin Park,1 Soo Hyeon Bae,1 Wan-Su Park,1 Seunghoon Han,1 Min-Ho Park,2 Seok-Ho Shin,2 Young G Shin,2 Dong-Seok Yim1,2 1Department of Clinical Pharmacology and Therapeutics, Seoul St Mary’s Hospital, PIPET (Pharmacometrics Institute for Practical Education and Training), College of Medi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Park G (Author), Bae SH (Author), Park W (Author), Han S (Author), Park M (Author), Shin S (Author), Shin YG (Author), Yim DS (Author)
Format:	Book
Published:	Dove Medical Press, 2017-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Exposure–response model for sibutramine and placebo: suggestion for application to long-term weight-control drug development
by: Han S, et al.
Published: (2015)

Application of physiologically based pharmacokinetic modeling in predicting drug–drug interactions for sarpogrelate hydrochloride in humans
by: Min JS, et al.
Published: (2016)

Drug–Drug–Gene Interactions in Cardiovascular Medicine
by: Asiimwe IG, et al.
Published: (2022)

Pharmacokinetic-Based Drug–Drug Interactions with Anaplastic Lymphoma Kinase Inhibitors: A Review
by: Zhao D, et al.
Published: (2020)

No Relevant Pharmacokinetic Drug–Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects
by: Kim YK, et al.
Published: (2021)

Changes in omeprazole pharmacokinetics in rats with diabetes induced by alloxan or streptozotocin: Faster clearance of omeprazole due to induction of hepatic CYP1A2 and 3A1
by: Dae Young Lee, et al.
Published: (2007)

A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug-Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine
by: Tobias Kanacher, et al.
Published: (2020)

Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management
by: Li W, et al.
Published: (2013)

Simultaneous Determination of Loratadine and Its Metabolite Desloratadine in Beagle Plasma by LC-MS/MS and Application for Pharmacokinetics Study of Loratadine Tablets and Omeprazole‑Induced Drug–Drug Interaction
by: Zhang Y, et al.
Published: (2021)

Variability of the drug response to nonsteroidal anti-inflammatory drugs according to cyclooxygenase-2 genetic polymorphism
by: Lee SJ, et al.
Published: (2017)

Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype
by: Chiaki Kamiya, et al.
Published: (2019)

Mechanisms and the clinical relevance of complex drug–drug interactions
by: Roberts AG, et al.
Published: (2018)

Comparative study of antiretroviral drug regimens and drug–drug interactions between younger and older HIV-infected patients at a tertiary care teaching hospital in South Korea
by: Park MS, et al.
Published: (2018)

Quantification of CYP3A and Drug Transporters Activity in Healthy Young, Healthy Elderly and Chronic Kidney Disease Elderly Patients by a Microdose Cocktail Approach
by: Punyabhorn Rattanacheeworn, et al.
Published: (2021)

Adverse drug reactions and drug–drug interactions with over-the-counter NSAIDs
by: Moore N, et al.
Published: (2015)

Inhibition of CYP1A1 by pharmaceutical drugs, omeprazol and ketoconazole as a mechanism for activation of aryl hydrocarbon receptor (AHR)
by: Ali Ghaffarian-Bahraman, et al.
Published: (2017)

Inhibition of CYP1A1 by pharmaceutical drugs, omeprazol and ketoconazole as a mechanism for activation of aryl hydrocarbon receptor (AHR)
by: Ali Ghaffarian-Bahraman, et al.
Published: (2017)

Drug–Drug Interactions Of Amiodarone And Quinidine On The Pharmacokinetics Of Eliglustat In Rats
by: Wang Q, et al.
Published: (2019)

Impact of fresh grape juice on the pharmacokinetics of omeprazole: results of a food-drug interaction study
by: Tayyaba Iftikhar, et al.
Published: (2024)

Physiologically‐based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors
by: Takashi Ueno, et al.
Published: (2021)

Investigation of clinical interaction between omeprazole and tacrolimus in CYP3A5 non-expressors, renal transplant recipients
by: Paraskevi F Katsakiori, et al.
Published: (2010)

Insights into CYP2B6-mediated drug-drug interactions
by: William D. Hedrich, et al.
Published: (2016)

No drug-drug interactions between selective prolyl‐tRNA synthetase inhibitor, bersiporocin, and pirfenidone or nintedanib in healthy participants
by: Wonsuk Shin, et al.
Published: (2024)

P-glycoprotein- and organic anion-transporting polypeptide-mediated transport of periplocin may lead to drug–herb/drug–drug interactions
by: Liang S, et al.
Published: (2014)

Omeprazole - a new raw material for drug compounding
by: Katarzyna Sosnowska, et al.
Published: (2023)

Drug-Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes
by: Florian Klomp, et al.
Published: (2020)

In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor
by: Heather Zhang, et al.
Published: (2021)

Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions?
by: Kim CO, et al.
Published: (2017)

Editorial: Incorporating Phase 0 microdosing as a powerful tool into a new vision of drug development
by: H. Markus Weiss, et al.
Published: (2024)

Ameliorating effect of microdoses of a potentized homeopathic drug, Arsenicum Album, on arsenic-induced toxicity in mice
by: Guha B, et al.
Published: (2003)

The therapeutic potential of microdosing psychedelics in depression
by: Kim P.C. Kuypers
Published: (2020)

Contribution of Trough Concentration Data in the Evaluation of Multiple-Dose Pharmacokinetics for Drugs with Delayed Distributional Equilibrium and Long Half-Life
by: Choi S, et al.
Published: (2020)

Evaluation of the relationship between polymorphisms in CYP2C19 and the single‐dose pharmacokinetics of omeprazole in healthy Chinese volunteers: A multicenter study
by: Shuang Zhou, et al.
Published: (2022)

Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model
by: Caifu Xue, et al.
Published: (2017)

Development of Prediction Models for Drug-Induced Cholestasis, Cirrhosis, Hepatitis, and Steatosis Based on Drug and Drug Metabolite Structures
by: Hyun Kil Shin, et al.
Published: (2020)

Physiologically‐based pharmacokinetic modeling for primary metabolites of CYP3A and P‐glycoprotein inhibitors in drug-drug interactions: Should we assume the free drug hypothesis?
by: Shinji Yamazaki, et al.
Published: (2023)

Herb-drug interaction studies of ethanolic extract of Cassia occidentalis L. coadministered with acetaminophen, theophylline, omeprazole, methotrexate and methylprednisolone
by: Athar Husain, et al.
Published: (2021)

Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug‐drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling
by: Felix Huth, et al.
Published: (2022)

Assessments of CYP‑inhibition‑based drug-drug interaction between vonoprazan and poziotinib in vitro and in vivo
by: Shan Zhou, et al.
Published: (2023)

Clinical assessment of momelotinib drug-drug interactions via CYP3A metabolism and transporters
by: Yu Liu Ho, et al.
Published: (2024)